Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers

Autor: Emanuele Saggese, Giorgio Silvestrelli, Alessia Lanari, Lucilla Parnetti, Paolo Reboldi
Rok vydání: 2005
Předmět:
Male
Aging
medicine.medical_specialty
Pathology
Alzheimer Disease
cerebrospinal fluid/diagnosis/etiology
Amyloid beta-Peptides
cerebrospinal fluid
Biological Markers
cerebrospinal fluid
Cognition Disorders
cerebrospinal fluid/complications/diagnosis
Female
Humans
Male
Peptide Fragments
cerebrospinal fluid
Predictive Value of Tests
tau Proteins
cerebrospinal fluid
Tau protein
tau Proteins
Gastroenterology
Central nervous system disease
Degenerative disease
Cerebrospinal fluid
cerebrospinal fluid/complications/diagnosis
Predictive Value of Tests
Internal medicine
mental disorders
medicine
Dementia
Humans
Pathological
Amyloid beta-Peptides
biology
cerebrospinal fluid/diagnosis/etiology
business.industry
medicine.disease
Peptide Fragments
Predictive value of tests
biology.protein
Biological Markers
Female
Alzheimer's disease
business
Cognition Disorders
Biomarkers
Developmental Biology
Zdroj: Mechanisms of ageing and development. 127(2)
ISSN: 0047-6374
Popis: Mild cognitive impairment (MCI) is an aetiologically heterogeneous syndrome. A correct prediction of MCI conversion to Alzheimer's disease (AD) represents a primary goal in routine clinical practice. Since the presence of pathological levels in >or=2 cerebrospinal fluid (CSF) biomarkers; amyloid protein (Abeta42), total tau (h-tau) and phospho-tau (p-tau) seems to reliably identifying MCI subjects converting to AD, we report our experience in a routine clinical setting. In the period from January 2001 to June 2003, 273 consecutive patients referred to our Memory Clinic for diagnostic assessment of cognitive impairment. Of them, 180 underwent a complete diagnostic evaluation including CSF dosage of fragment 1-42 of amyloid protein, total tau and phospho-tau (ELISA Method, Innogenetics, Gent, Belgium), after vascular or other secondary causes of dementia could be excluded. At baseline, 38% of the MCI subjects (20/55) showed pathological levels in >or=2 CSF biomarkers. After 1 year, 11 MCI patients converted to dementia, 33 remained stable, 11 showed a further progression of cognitive impairment still not fulfilling the diagnostic criteria for dementia. Of the 11 converters, 10 showed >or=2 pathological values CSF biomarkers and in all of them, p-tau was high. On the contrary, 29 out of 33 stable MCI (88%) showed no or one pathological CSF value. We confirm that pathological levels in >or=2 CSF biomarkers reliably predict MCI conversion to AD and correctly identify the stable form of MCI.
Databáze: OpenAIRE
Externí odkaz: